COVID19 therapeutics: Expanding the antiviral arsenal.
作者信息
Gallagher Tom
机构信息
Department of Microbiology and Immunology, Loyola University Chicago, Maywood, Illinois, USA.
出版信息
EBioMedicine. 2021 Apr;66:103289. doi: 10.1016/j.ebiom.2021.103289. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
COVID19 therapeutics: Expanding the antiviral arsenal.新冠病毒治疗方法：扩充抗病毒武器库。
EBioMedicine. 2021 Apr;66:103289. doi: 10.1016/j.ebiom.2021.103289. Epub 2021 Mar 19.
2
RNASeq profiling of COVID19-infected patients identified an EIF2AK2 inhibitor as a potent SARS-CoV-2 antiviral.对新冠病毒感染患者的RNA测序分析确定了一种EIF2AK2抑制剂是一种有效的抗新冠病毒药物。
Clin Transl Med. 2022 Nov;12(11):e1098. doi: 10.1002/ctm2.1098.
3
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
4
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.重新利用治疗方法以潜在治疗 SARS-CoV-2：综述。
Viruses. 2020 Jun 30;12(7):705. doi: 10.3390/v12070705.
5
Current development of COVID-19 diagnostics, vaccines and therapeutics.新型冠状病毒肺炎诊断、疫苗和治疗药物的最新进展。
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
6
Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence.抗疟药物在 SARS-CoV-2 治疗中并非一概而论：一项计算分析证据。
Curr Pharm Des. 2021;27(10):1323-1329. doi: 10.2174/1381612826666201210092736.
7
Tracking a Vaccine and Developing Therapeutics for COVID-19.追踪新冠疫苗及研发新冠治疗方法
Dimens Crit Care Nurs. 2020 Nov/Dec;39(6):293-297. doi: 10.1097/DCC.0000000000000447.
8
Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.使用多梳蛋白抑制剂作为抗病毒药物靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）
Epigenomics. 2020 May;12(10):811-812. doi: 10.2217/epi-2020-0154. Epub 2020 Jun 4.
9
Computational Approaches for Development of Engineered Therapeutics against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）开发工程治疗药物的计算方法。
Biochemistry. 2023 Feb 7;62(3):669-671. doi: 10.1021/acs.biochem.2c00629. Epub 2022 Dec 30.
10
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.寻找 SARS-CoV-2/COVID-19 治疗方法的艰难途径。
J Antimicrob Chemother. 2020 Sep 1;75(9):2381-2383. doi: 10.1093/jac/dkaa272.
引用本文的文献
1
Inhibition of Toll-like receptor 4 and Interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury.抑制Toll样受体4和白细胞介素-1受体可预防新型冠状病毒介导的肾损伤。
Cell Death Discov. 2023 Aug 10;9(1):293. doi: 10.1038/s41420-023-01584-x.
2
A Fungal Defensin Targets the SARS-CoV-2 Spike Receptor-Binding Domain.一种真菌防御素靶向新冠病毒刺突蛋白受体结合域。
J Fungi (Basel). 2021 Jul 12;7(7):553. doi: 10.3390/jof7070553.
3
Protease Inhibition-An Established Strategy to Combat Infectious Diseases.蛋白酶抑制：防治传染病的成熟策略。
Int J Mol Sci. 2021 May 28;22(11):5762. doi: 10.3390/ijms22115762.
Zotero 插件